Quest Diagnostics Reports Third Quarter 2026 Financial Results; Raises Revenue and EPS Guidance for Full Year 2026
Third quarter revenues of $3.10 billion, up 10.0% from 2025, on strong organic revenue growth Third quarter reported diluted earnings per share ("EPS") of $2.78, up 28.7% from 2025; and adjusted diluted EPS of $3.00, up 15.4% from 2025 Full year 2026 revenues now expected to be between...
Covered in this story
Analyst targets on Quest Diagnostics
- Truist Securities: $228 → $250 by Jul 2027 · Hold via Investing.com
Published targets verified against independent reporting and tracked to their dates. Not recommendations from Dalsna Finance.
Call it yourself
No member calls on $DGX yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Quest Diagnostics →Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.